| | | | 09/08/16 | Tokai Pharmaceuticals Announces Review of Strategic Alternatives| BOSTON--(BUSINESS WIRE)--Sep. 8, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that its Board of Directors has initiated a review of strategic
alternatives for the company focused on maximizing stockholder value.
Potential strategic alternatives that may be explored or evaluated a... |
|  |  | | 07/29/16 | Tokai Pharmaceuticals Announces Reduction in Force| BOSTON--(BUSINESS WIRE)--Jul. 29, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that it is reducing its workforce by approximately 60 percent, to a
total of 10 full-time equivalent employees, under a plan expected to be
largely completed by the end of the third quarter of 2016. This
... |
| | | | 07/26/16 | Tokai Pharmaceuticals Announces Clinical Update| Company to Discontinue Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7
Positive mCRPC
Tokai to Host Conference Call Today at 8:30 AM E.T.
BOSTON--(BUSINESS WIRE)--Jul. 26, 2016--
Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that it plans to discontinue the ARMOR3-SV cli... |
| | |
|
0.02 (1.29%)09/30/164:00 p.m. ET
Print Page | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Financial Tear Sheet